+

WO2000001813A3 - Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene - Google Patents

Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene Download PDF

Info

Publication number
WO2000001813A3
WO2000001813A3 PCT/CA1999/000604 CA9900604W WO0001813A3 WO 2000001813 A3 WO2000001813 A3 WO 2000001813A3 CA 9900604 W CA9900604 W CA 9900604W WO 0001813 A3 WO0001813 A3 WO 0001813A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgen
independent activation
androgen receptor
receptor
activation
Prior art date
Application number
PCT/CA1999/000604
Other languages
English (en)
Other versions
WO2000001813A2 (fr
Inventor
Marianne D Sadar
Nicholas Bruchovsky
Peter W Gout
Robert Snoek
Nasrin R Mawji
Original Assignee
Univ British Columbia
Marianne D Sadar
Nicholas Bruchovsky
Peter W Gout
Robert Snoek
Nasrin R Mawji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Marianne D Sadar, Nicholas Bruchovsky, Peter W Gout, Robert Snoek, Nasrin R Mawji filed Critical Univ British Columbia
Priority to AU44943/99A priority Critical patent/AU4494399A/en
Priority to CA002302169A priority patent/CA2302169A1/fr
Publication of WO2000001813A2 publication Critical patent/WO2000001813A2/fr
Publication of WO2000001813A3 publication Critical patent/WO2000001813A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'activation indépendante de l'androgène du récepteur d'androgène est localisée dans la région comprenant les acides aminés 234-391 de la protéine du récepteur d'androgène humain. L'invention concerne des peptides dérivés et des acides nucléiques codant pour ces peptides. Ces peptides sont utiles comme domaines d'activation, comme inhibiteurs de l'activation indépendante des androgènes du récepteur d'androgène, et comme agents thérapeutiques pour des pathologies d'origine androgénique telles que le cancer de la prostate. L'invention concerne en outre des procédés permettant la sélection de composés affectant l'activation indépendante de l'androgène du récepteur d'androgène.
PCT/CA1999/000604 1998-06-30 1999-06-30 Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene WO2000001813A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU44943/99A AU4494399A (en) 1998-06-30 1999-06-30 Inhibitors of androgen-independent activation of androgen receptor
CA002302169A CA2302169A1 (fr) 1998-06-30 1999-06-30 Inhibiteurs du phenomene d'activation ne dependant pas de l'androgene et ayant un effet sur le recepteur de l'androgene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9187198P 1998-06-30 1998-06-30
US60/091,871 1998-06-30

Publications (2)

Publication Number Publication Date
WO2000001813A2 WO2000001813A2 (fr) 2000-01-13
WO2000001813A3 true WO2000001813A3 (fr) 2000-04-13

Family

ID=22230037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000604 WO2000001813A2 (fr) 1998-06-30 1999-06-30 Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene

Country Status (3)

Country Link
AU (1) AU4494399A (fr)
CA (1) CA2302169A1 (fr)
WO (1) WO2000001813A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003018987A (ja) * 2001-06-25 2003-01-21 Okazaki National Research Institutes 遺伝子導入細胞及びそれを用いた撹乱物質の検出法
US20100189776A1 (en) 2007-03-16 2010-07-29 Cancer Research Technology Ltd Anti-androgen peptides and uses thereof in cancer therapy
WO2009033212A1 (fr) * 2007-09-11 2009-03-19 Christopher Hovens Utilisation de protéines de liaison aux œstrogènes et aux androgènes dans des procédés et compositions pour le traitement de cancers gynécologiques
FR2938334A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de l'adfp dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
CN102083780B (zh) 2008-07-02 2017-03-29 不列颠哥伦比亚癌症局分支机构 二缩水甘油醚衍生物治疗剂和它们的使用方法
AU2009284668B2 (en) 2008-08-22 2015-07-09 British Columbia Cancer Agency Branch Small molecule inhibitors of N-terminus activation of the androgen receptor
JP5940982B2 (ja) 2010-01-06 2016-06-29 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲンレセプター活性調節因子としての、ビスフェノール誘導体およびその使用
US20140248263A1 (en) 2011-04-08 2014-09-04 The University Of British Columbia Bisphenol compounds and methods for their use
ES2613098T3 (es) 2011-08-19 2017-05-22 British Columbia Cancer Agency Branch Compuestos de éter de bisfenol fluorado y métodos para su uso
GB2496135B (en) 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
GB2513615A (en) 2013-05-01 2014-11-05 Cancer Rec Tech Ltd Medical use
KR20170060162A (ko) 2013-05-10 2017-05-31 브리티쉬 콜롬비아 캔써 에이전시 브랜치 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법
US9375496B2 (en) 2013-09-09 2016-06-28 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
US9682933B2 (en) 2014-05-30 2017-06-20 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use
PL3988541T3 (pl) 2015-01-13 2024-12-16 British Columbia Cancer Agency Branch Związki heterocykliczne do obrazowania i leczenia nowotworów oraz sposoby ich zastosowania
WO2016141458A1 (fr) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Dérivés d'éther de bisphénol et leurs procédés d'utilisation
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2018029517A1 (fr) * 2016-08-08 2018-02-15 Olipass Corporation Oligonucléotides antisens du récepteur des androgènes
WO2019226991A1 (fr) 2018-05-25 2019-11-28 Essa Pharma, Inc. Modulateurs du récepteur des androgènes et leurs procédés d'utilisation
PE20211543A1 (es) 2018-10-18 2021-08-16 Essa Pharma Inc Moduladores del receptor de androgenos y metodos para su uso
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP4135675A4 (fr) 2020-04-17 2024-04-10 Essa Pharma, Inc. Formes solides d'un inhibiteur de récepteur des androgènes de domaine n-terminal et leurs utilisations
WO2023046283A1 (fr) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Composés et leur utilisation dans une méthode de modulation de l'activité transcriptionnelle d'ar (récepteur des androgènes)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009791A1 (fr) * 1988-04-14 1989-10-19 University Of North Carolina At Chapel Hill Adn codant pour des proteines receptrices d'androgene
EP0577932A2 (fr) * 1992-05-08 1994-01-12 American Cyanamid Company Développement d'un "screening" basé en mécanisme pour identifier agonistes et antagonistes du récepteur d'androgène
WO1997030074A1 (fr) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation et utilisation de peptides de liaison de sh3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009791A1 (fr) * 1988-04-14 1989-10-19 University Of North Carolina At Chapel Hill Adn codant pour des proteines receptrices d'androgene
EP0577932A2 (fr) * 1992-05-08 1994-01-12 American Cyanamid Company Développement d'un "screening" basé en mécanisme pour identifier agonistes et antagonistes du récepteur d'androgène
WO1997030074A1 (fr) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation et utilisation de peptides de liaison de sh3

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHAMBERLAIN, N L ET AL.,: "Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 43, 25 October 1996 (1996-10-25), pages 26772 - 26778, XP002130096 *
CULIG Z ET AL.,: "Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor", CANCER RESEARCH, vol. 54, 15 October 1994 (1994-10-15), pages 5474 - 5478, XP000867802 *
DE RUITER PE ET AL.,: "Synergism between androgens and protein kinase-C on androgen regulated gene expression", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 110, 1995, pages r1 - r6, XP000874779 *
JENSTER G ET AL.,: "Identification of two transcription activation units in the N-terminal domain of the human androgen receptor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7341 - 7346, XP000867758 *
JIA L D ET AL: "Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 61, no. 9, 1996, pages 531-539, XP004070285, ISSN: 0039-128X *
NAZARETH LV AND WEIGEL NL: "Activation of human androgen receptor through a protein kinase A signaling pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 19900 - 19907, XP002130095 *
SADAR MD: "Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 12 March 1999 (1999-03-12), pages 7777 - 7783, XP002130097 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Also Published As

Publication number Publication date
CA2302169A1 (fr) 2000-01-13
AU4494399A (en) 2000-01-24
WO2000001813A2 (fr) 2000-01-13

Similar Documents

Publication Publication Date Title
WO2000001813A3 (fr) Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene
WO2000040614A3 (fr) Caracterisation d'une famille de canaux calciques
MY120693A (en) Human bikunin
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
CA2184908A1 (fr) Cathepsine derivee d'osteoclaste humain
WO2001036640A3 (fr) Gene humain fgf-21 et produits d'expression genique
EP1194164B8 (fr) Peptides proteiniques du prion et utilisations associees
EP2258383A3 (fr) Peptides antigènes dérivés de la télomérase
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
ATE299510T1 (de) Peptide als kalium kanalaktivatoren
WO2003016342A3 (fr) Antigenes tumoraux pour la prevention et/ou le traitement du cancer
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
WO2002094859A3 (fr) Peptides mage-a1 permettant le traitement ou la prevention du cancer
AU7525398A (en) Inhibitors for urokinase receptor
WO2002034915A3 (fr) Segments preferes de la proteine neurale ntp et ses procedes d'utilisation
PT938329E (pt) Composicao de tlp imunogenica
BR0008917A (pt) Compostos
WO2000024771A3 (fr) Acides nucleiques codant pour des proteines semblables a l'osteoprotegerine et methodes d'utilisation associees
IL128546A0 (en) Cycloalkyl inhibitors of protein farnesyltransferase
WO2002030977A3 (fr) Proteine a motif egf, materiaux egfl6 et procedes
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2003042700A3 (fr) Polypeptide associe au cancer du sein
AU2375895A (en) Methods for detection and therapy of squamous cell carcinoma and bladder carcinoma, in particular for determining the pr esence and treatment of minimal residual disease, micrometas tases or dissemination of such carcinoma types

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2302169

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09515886

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载